ILK predicts the efficacy of chemoradiotherapy and the prognosis of patients with esophageal squamous cell carcinoma

Ma,Xiao‑Li; Yao,Hua; Wang,Xiao; Wei,Yu; Cao,Lei‑Yu; Zhang,Qian; Zhang,Li

doi:10.3892/ol.2019.10768

ILK predicts the efficacy of chemoradiotherapy and the prognosis of patients with esophageal squamous cell carcinoma

Authors:
- Xiao‑Li Ma
- Hua Yao
- Xiao Wang
- Yu Wei
- Lei‑Yu Cao
- Qian Zhang
- Li Zhang
View Affiliations

Affiliations: Department of Internal Medicine VIP, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uyghur Autonomous Region 830011, P.R. China, Department of Health Management Center, Xinjiang Medical University, Urumqi, Xinjiang Uyghur Autonomous Region 830011, P.R. China
Published online on: August 22, 2019 https://doi.org/10.3892/ol.2019.10768
Pages: 4114-4125
Copyright: © Ma et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Isobaric tags for relative and absolute quantitation (iTRAQ) technology was adopted to screen differentially‑expressed proteins in the serum that predict the effects of chemoradiotherapy on esophageal squamous cell carcinoma (ESCC). Thus, significantly related proteins can be functionally identified at the cellular level. A total of 60 patients diagnosed with locally advanced and advanced ESCC were recruited and treated with chemoradiotherapy. The iTRAQ technique was used to screen serum differentially expressed proteins associated with chemoradiotherapeutic efficacy. Functional identification of significantly related proteins was performed at the cellular level. Cell proliferation was detected using MTT, clonogenic and fluorescence assays, and apoptosis was assessed using flow cytometry. Transwell and wound‑healing assays were used to detect the invasion and migration properties of cancer cells. Proteomics results revealed that prior to chemoradiotherapy, the expression level of integrin‑linked kinase (ILK) was significantly upregulated in patients with ESCC, compared with that of the control group [ratio (r)=4.386; P<0.05], and significantly downregulated in the chemoradiotherapy‑sensitive group, compared with the chemoradiotherapy‑resistant group (r=0.587; P<0.05). At the cellular level, the proliferation rate of cells in the experimental group was significantly inhibited (P<0.05), and the number of cell colonies was decreased (P<0.01), while the number of apoptotic cells was significantly increased (P<0.01). The invasive ability of TE‑1 cells in the shILK group was significantly inhibited (P<0.01), and the migration rate was significantly retarded at 8 and 24 h (P<0.01). The present study highlighted the potential value of ILK in predicting the efficacy of chemoradiotherapeutic treatment in patients with ESCC, and that ILK gene‑silencing inhibits the progression of ESCC.

View Figures

View References

1	Soerjomataram I, Lortet-Tieulent J, Parkin DM, Ferlay J, Mathers C, Forman D and Bray F: Global burden of cancer in 2008: A systematic analysis of disability-adjusted life-years in 12 world regions. Lancet. 380:1840–1850. 2012. View Article : Google Scholar : PubMed/NCBI
2	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
3	Napier KJ, Scheerer M and Misra S: Esophageal cancer: A Review of epidemiology, pathogenesis, staging workup and treatment modalities. World J Gastrointest Oncol. 6:112–120. 2014. View Article : Google Scholar : PubMed/NCBI
4	Jemal A, Clegg LX, Ward E, Ries LA, Wu X, Jamison PM, Wingo PA, Howe HL, Anderson RN and Edwards BK: Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival. Cancer. 101:3–27. 2004. View Article : Google Scholar : PubMed/NCBI
5	Doi T, Piha-Paul SA, Jalal SI, Saraf S, Lunceford J, Koshiji M and Bennouna J: Safety and antitumor activity of the anti-programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma. J Clin Oncol. 36:61–67. 2018. View Article : Google Scholar : PubMed/NCBI
6	Pennathur A, Gibson MK, Jobe BA and Luketich JD: Oesophageal carcinoma. Lancet. 381:400–412. 2013. View Article : Google Scholar : PubMed/NCBI
7	Giri S, Pathak R, Aryal MR, Karmacharya P, Bhatt VR and Martin MG: Incidence trend of esophageal squamous cell carcinoma: An analysis of Surveillance Epidemiology and End Results (SEER) database. Cancer Causes Control. 26:159–161. 2015. View Article : Google Scholar : PubMed/NCBI
8	Zhang J, Zhi C, Zhen F, Yuan X, Jiao C, Zhu H, Zhu H and Feng Y: iTRAQ-based quantitative proteomic analyses of high grade esophageal squamous intraepithelial neoplasia. Proteomics Clin Appl. Dec 11–2017.(Epub ahead of print). doi: 10.1002/prca.201600167. View Article : Google Scholar
9	Hsu CH, Hsu CW, Hsueh C, Wang CL, Wu YC, Wu CC, Liu CC, Yu JS, Chang YS and Yu CJ: Identification and characterization of potential biomarkers by quantitative tissue proteomics of primary lung adenocarcinoma. Mol Cell Proteomics. 15:2396–2410. 2016. View Article : Google Scholar : PubMed/NCBI
10	Rice TW: Esophageal cancer staging. Korean J Thorac Cardiovasc Surg. 48:157–163. 2015. View Article : Google Scholar : PubMed/NCBI
11	Young J, Badgery-Parker T, Dobbins T, Jorgensen M, Gibbs P, Faragher I, Jones I and Currow D: Comparison of ECOG/WHO performance status and ASA score as a measure of functional status. J Pain Symptom Manage. 49:258–264. 2015. View Article : Google Scholar : PubMed/NCBI
12	Bandaranayake AD, Correnti C, Ryu BY, Brault M, Strong RK and Rawlings DJ: Daedalus: A robust, turnkey platform for rapid production of decigram quantities of active recombinant proteins in human cell lines using novel lentiviral vectors. Nucleic Acids Res. 39:e1432011. View Article : Google Scholar : PubMed/NCBI
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta DeltaC (T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
14	Ohashi S, Miyamoto S, Kikuchi O, Goto T, Amanuma Y and Muto M: Recent advances from basic and clinical studies of esophageal squamous cell carcinoma. Gastroenterology. 149:1700–1715. 2015. View Article : Google Scholar : PubMed/NCBI
15	Herskovic A, Russell W, Liptay M, Fidler MJ and Al-Sarraf M: Esophageal carcinoma advances intreatment results for locally advanced disease: Review. Ann Oncol. 23:1095–1103. 2012. View Article : Google Scholar : PubMed/NCBI
16	Li BZ, Chen ZL, Shi SS, Feng XL, Tan XG, Zhou F and He J: Overexpression of Cdc25C predicts response to radiotherapy and survival in esophageal squamous cell carcinoma patients treated with radiotherapy followed by surgery. Chin J Cancer. 32:403–409. 2013.PubMed/NCBI
17	Sugase T, Takahashi T, Serada S, Fujimoto M, Hiramatsu K, Ohkawara T, Tanaka K, Miyazaki Y, Makino T, Kurokawa Y, et al: SOCS1 gene therapy improves radiosensitivity and enhances irradiation-induced DNA damage in esophageal squamous cell carcinoma. Cancer Res. 77:6975–6986. 2017. View Article : Google Scholar : PubMed/NCBI
18	Tamaoki M, Komatsuzaki R, Komatsu M, Minashi K, Aoyagi K, Nishimura T, Chiwaki F, Hiroki T, Daiko H, Morishita K, et al: Multiple roles of single-minded 2 in esophageal squamous cell carcinoma and its clinical implications. Cancer Sci. 109:1121–1134. 2018. View Article : Google Scholar : PubMed/NCBI
19	Shigaki H, Baba Y, Watanabe M, Murata A, Ishimoto T, Iwatsuki M, Iwagami S, Nosho K and Baba H: PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma. Clin Cancer Res. 19:2451–2459. 2013. View Article : Google Scholar : PubMed/NCBI
20	Hannigan GE, Leung-Hagesteijn C, Fitz-Gibbon L, Coppolino MG, Radeva G, Filmus J, Bell JC and Dedhar S: Regulation of cell adhesion and anchorage-dependent growth by a new beta 1-integrin-linked protein kinase. Nature. 379:91–96. 1996. View Article : Google Scholar : PubMed/NCBI
21	Wong RP, Ng P, Dedhar S and Li G: The role of integrin-linked kinase in melanoma cell migration, invasion and tumor growth. Mol Cancer Ther. 6:1692–1700. 2007. View Article : Google Scholar : PubMed/NCBI
22	Zhuang X, Lv M, Zhong Z, Zhang L, Jiang R and Chen J: Interplay between intergrin-linked kinase and ribonuclease inhibitor affects growth and metastasis of bladder cancer through signaling ILK pathways. J Exp Clin Cancer Res. 35:1302016. View Article : Google Scholar : PubMed/NCBI
23	Shen H, Ma JL, Zhang Y, Deng GL, Qu YL, Wu XL, He JX, Zhang S and Zeng S: Integrin-linked kinase overexpression promotes epithelial-mesenchymal transition via nuclear factor-κB signaling in colorectal cancer cells. World J Gastroenterol. 22:3969–3977. 2016. View Article : Google Scholar : PubMed/NCBI
24	Driver GA and Veale RB: Modulation of integrin-linked kinase (ILK) expression in human oesophageal squamous cell carcinoma cell lines by the EGF and TGFbeta1 growth factors. Cancer Cell Int. 6:122006. View Article : Google Scholar : PubMed/NCBI
25	Mohamed MS, Bishr MK, Almutairi FM and Ali AG: Inhibitors of apoptosis: Clinical implications in cancer. Apoptosis. 22:1487–1509. 2017. View Article : Google Scholar : PubMed/NCBI
26	Duxbury MS, Ito H, Benoit E, Waseem T, Ashley SW and Whang EE: RNA interference demonstrates a novel role for integrin-linked kinase as a determinant of pancreatic adenocarcinoma cell gemcitabine chemoresistance. Clin Cancer Res. 11:3433–839. 2005. View Article : Google Scholar : PubMed/NCBI
27	Lanvin O, Monferran S, Delmas C, Couderc B, Toulas C and Cohen-Jonathan-Moyal E: Radiation-induced mitotic cell death and glioblastoma radioresistance: A new regulating pathway controlled by integrin-linked kinase, hypoxia-inducible factor 1 alpha and survivin in U87 cells. Eur J Cancer. 49:2884–2891. 2013. View Article : Google Scholar : PubMed/NCBI